Roche announced that its immunotherapy Tecentriq failed a late-stage clinical trial in a form of urothelial cancer.
According to the drugmaker, the Phase III IMvigor010 study evaluating Tecentriq as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.
The goal in treating MIUC early is to reduce the risk of the disease recurring or spreading to other parts of the body. More treatment options following surgery are needed as approximately half of people with MIUC will develop a recurrence of their disease within two years of surgery.
Tecentriq is already approved in the U.S., EU and other countries for treating various forms of non-small cell and small cell lung cancer, some kinds of metastatic urothelial cancer, and in PD-L1-positive metastatic triple-negative breast cancer. Roche has active Phase III studies for Tecentriq in early and advanced bladder cancer.
Read the press release
